BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma

By afschroeder • August 8, 2026

Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer J, Parikh ND, Pillai A, Salem R, Sapisochin G, Tabrizian P, Yopp A, Yarchoan M; HCC-Live Steering Committee. BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026 Aug 7. doi: 10.1097/HEP.0000000000001834. Epub ahead of print. PMID: 42565685.

Tags: Hematology/Oncology, immunotherapy, liver cancer, locoregional therapy, Publications, Treatment

Related Posts

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer

Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar[...]

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]